Skip to content

Biobank 3 Hoorn Diabetes Care System Cohort follow up 2023

Biobank 3 Hoorn Diabetes Care System Cohort follow up 2023 - BB3

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53604
Enrollment
2500
Registered
2023-06-21
Start date
2024-01-10
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes insulin insensitivity

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - All adult newly diagnosed patients with T2D in the Hoorn DCS, who have not yet been asked to participate in research; - All DCS participants with T2D who have previously provided informed consent to be contacted for research.

Exclusion criteria

Exclusion criteria: • Unable to give written informed consent. • Serious mental impairment i.e. preventing to understand the study protocol / aim.

Design outcomes

Primary

MeasureTime frame
The primary endpoint are diabetes progression and incident diabetes complications, including microvascular complications (foot complications, retinopathy, nephropathy), macrovascular complications (cardiovascular disease, including myocardial infarction, angina pectoris, heart failure, stroke, transient ischaemic attack and peripheral arterial disease) as well as all-cause and cause-specific mortality.

Secondary

MeasureTime frame
Secondary endpoints include diabetes progression measured as anthropometrics, metabolic status, prevalence and severity of non-alcoholic fatty liver disease (NAFLD), medication use, psychological complications and quality of life.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)